摘要
目的本文比较常规剂量和大剂量ＶＩＰ方案化疗对小鼠Ｌｅｗｉｓ肺癌的疗效，同时分析应用体外扩增的骨髓细胞进行移植治疗的可行性。方法骨髓细胞采用微血管内皮细胞共培养方法进行体外培养扩增。Ｃ５７ＢＬ／６Ｊ小鼠皮下接种１×１０６Ｌｅｗｉｓ肺癌细胞，接种后第３天和第１４天分别进行常规剂量和大剂量ＶＩＰ方案化疗。常规剂量ＶＩＰ方案（ＶＩＰＣＤ）为顺铂（４ｍｇ／ｋｇ，腹腔注射，第１天），异环磷酰胺（２００ｍｇ／ｋｇ，腹腔注射，第２天）和依托帕甙（２ｍｇ／ｋｇ，腹腔注射，第１～２天）。大剂量ＶＩＰ方案（ＶＩＰＨＤ）是将上述药物的剂量分别提高２．５倍，用法同上。ＶＩＰＨＤ化疗后２４ｈ经尾静脉移植３×１０６体外扩增的骨髓细胞。采用定期测量肿瘤体积和随访小鼠生存时间进行疗效评定。结果对早期肿瘤（接种后３天，平均肿瘤直径为０．５ｃｍ），ＶＩＰＣＤ化疗明显抑制肿瘤生长；但对接种后２周的巨大肿瘤（平均肿瘤直径１．５ｃｍ），应用该方案间隔２周连续治疗３个疗程仍不能有效控制肿瘤生长。上述实验中ＶＩＰＣＤ治疗组的中位生存期与对照组相比无统计学显著差异（Ｐ＞０．０５）。与此相反，单次ＶＩＰＨＤ化疗和骨髓移植显著控制了早期肿瘤生长，使治愈率达到９?
bjective:To evaluate the efficacy of conventionaldose and highdose chemotherapy on mouse Lewis lung cancer and the feasibility of transplantation with bone marrow cells expanded ex vivo. Methods:Mouse Lewis lung cancer cells were inoculated s.c.into C57BL/6J mice.The dosage of VIP regimen(cisplatin, ifosfamide, and etoposide)in highdose chemotherapy(VIPHD)was 2.5fold higher than in conventional dose chemotherapy (VIPCD). Mouse bone marrow cells were expanded ex vivo and then injected i.v.into each mouse after VIP treatment.Results:The VIPCD markedly inhibited the growth of early tumors, but failed for larger tumors even after three cycles of VIPCD; the median survival of these mice time did not differ significantly from those untreated control (P>0.05). In contrast, single cycle of VIPHD with bone marrow cell infusion eradicated 90% of early tumors, three cycles decreased tumor volume by more than 30% in 9/10 mice and increased survival time significantly. Conclusion: As for mouse Lewis lung cancer, VIPHD can significantly improve the therapeutic outcome than the VIPCD and with a cure rate from 60 % to 90 %.These data suggest a promising value for use in clinical treatment. It also indicates that bone marrow cells expanded ex vivo can be safely reinfused after multicycle highdose chemotherapy.
出处
《肿瘤》
CAS
CSCD
北大核心
1998年第2期71-75,共5页
Tumor
关键词
LEWIS
肺肿瘤
药物疗法
剂量
骨髓移植
体外扩增
Highdose chemotherapy Bone marrow cell transplantation Mouse Lewis lung cancer
